“Botanicals Market Report is set to have rapid growth due to increased consumer awareness for preventive healthcare, aging population, increasing prevalence of chronic problems, assurance of no side effects at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Botanicals Market Forecast 2019-2029: By Intervention (Ayurveda, Naturopathy & Homeopathy), By Distribution Channel (Direct Sales, E-commerce), By Region And Segment Forecasts.

For centuries, natural products, extracts and natural products have been used as a form of treatment for various acute and chronic disorders. Over time, various improvements have been made to natural products that have led to a correct dosage and properties from raw forms and are now classified under the name of botanical products / herbal supplements / natural supplements.

Botanical products on the market are available in various forms including oils, tablets, herbs, powders. Even in this advanced age, botanical products are widely used by almost all population groups ranging from newborns, youngsters and adults. People are adopting botanical products for almost all types of ailments such as dietary supplements for chronic pain and injury treatment. Greater consumer awareness for preventive health care together with an aging population, an increase in the prevalence of chronic problems such as cardiovascular disease, diabetes, obesity, and a greater belief that there are no side effects unlike modern medicine were the main ones factors that have contributed to the growth of the market.

Leading companies featured in the report include Dabur, Ricola, Herbalife, Himalaya, Omega Protein Corp., Amway, Bayer AG, Naturalife Asia Co., Bio-Botanica Inc. and Nature's Bounty Co.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever